Rezolute, Inc. 10-Q — AI Bull & Bear Analysis

Rezolute stands at a critical crossroads where the outcome of H2 2026 will likely determine the company's viability. The synthesis of the latest filing reveals a company with significant intellectual property and a high-potential asset in ersodetug, but one that is operating under extreme regulatory and financial pressure. The shift in spending toward general and administrative costs suggests a bet on near-term commercialization, yet the lack of revenue and the depletion of liquid cash create a high-stakes environment. Investors are essentially weighing the probability of the FDA accepting a non-traditional data package for sunRIZE and the success of the upLIFT trial against a backdrop of inevitable dilution and capital constraints. The $120 million in total liquidity provides a temporary shield, but the transition to a commercial entity will require not only regulatory wins but likely additional capital raises, given the substantial milestone obligations to XOMA and ActiveSite.